How I Treat Epithelial Ovarian Cancer during COVID-19 Pandemic

Coronavirus disease 2019 (COVID-19) pandemic is accelerating in an unprecedented manner, with 3,175,207 confirmed cases and 224,172 deaths worldwide.[1] Studies from China and Italy reported that individuals with cancer have a two-fold higher rate of COVID-19 infection and a ten-fold higher risk of mortality as compared to individuals patients without cancer.[2-4] Cancer caregivers are battling in the wake of a scarcity of workforce, personal protective equipment, medications, and risk of COVID-19 infection. This catastrophic situation warrants a relook of management of epithelial ovarian cancer adapted to the local context. Various guidelines on ovarian cancer management and publications of landmark trials were reviewed in this regard, and the latest literature on COVID-19 was studied.[5,6] These are the suggestions from science and cost-care consortium for managing ovarian cancer patients during the COVID-19 pandemic [Table 1].

Newly Diagnosed Ovarian Cancer

The intent of early-stage (I/II) ovarian cancer is curative, so it should be managed with primary debulking surgery (PDS) and adjuvant chemotherapy for 3–6 cycles. In view of COVID-19, the European Society of Medical Oncology prioritize newly diagnosed ovarian cancer selected for PDS as a medium priority, and it can be deferred by 4 weeks.[7] Similarly, the Society of Gynecologic Oncology (SGO) classifies PDS for newly diagnosed early-stage ovarian cancer as a Tier 2A/B (nonurgent) category of Modified Elective Surgery Acuity Scale and can be delayed by 4–12 weeks.[8] There is no change in the standard surgical staging procedure for PDS. An open approach should be considered rather than laparoscopy, as it can generate aerosols.[9]

Stage III/limited stage IV carcinoma ovary patients are managed with PDS followed by adjuvant chemotherapy or neoadjuvant therapy (NACT) followed by interval debulking surgery (IDS) and further adjuvant chemotherapy. The neoadjuvant treatment is employed to achieve rapid clinical response, low operative morbidity, and optimal debulking surgery.[10] As prior surgery is associated with significant mortality in COVID-19 patients with cancer.[3] Hence, it is vital to start NACT rather than PDS for a newly diagnosed patient of stage III/IV ovarian cancer. The recent COVID-19 guideline for SGO classifies IDS as Tier 3A/B (semi-urgent). The decision for IDS after 3–4 cycles of NACT can be delayed up to 1–4 weeks.[8,11,12]

The goal of adjuvant therapy after PDS or NACT is to consolidate the benefits achieved so far. Adjuvant chemotherapy is beneficial if it is started within 3–6-week postsurgery.[13,14] Unless compelling, it is prudent to delay adjuvant therapy until 6-week post-surgery in the current scenario.

Relapsed Ovarian Cancer

Platinum-sensitive ovarian cancer should be treated aggressively, as the outcome is better as compared to platinum-resistant/refractory cancer. It can be treated with 4-weekly regimens such as liposomal doxorubicin-carboplatin instead of 3-weekly and weekly therapies. The 3-weekly therapies, such as carboplatin and paclitaxel, can be continued as 4-weekly to decrease the hospital footfall.[7] Imaging should be done every two cycles to document treatment response. For chemotherapy responders, an early switch to oral maintenance therapy is warranted. Palliative chemotherapy for elderly or poor performance status employing weekly chemotherapy requires frequent hospital visits. These may be converted to 3-weekly regimens of single-agent carboplatin with an area under curve 5 (AUC-5) or carboplatin AUC-5 and paclitaxel 135 mg/m² to mitigate the crisis.[15,16] Primary prophylaxis with granulocyte colony-stimulating factor can be used to prevent leukopenia.

Platinum-resistant cancer can be managed with oral cyclophosphamide with bevacizumab with similar benefit as compared to the standard regimens employing intravenous chemotherapy and bevacizumab with a progression-free survival of 5 months and 6.7 months, respectively.[17,18] For platinum-refractory carcinoma ovary, oral metronomic therapy with cyclophosphamide and etoposide or melphalan may be considered.

Recent evidence showed higher blood vascular endothelial growth factor (VEGF) levels in COVID-19 patients as compared to healthy controls. VEGF is a significant biomarker of endothelial injury and a potential therapeutic target in viral acute lung injury and acute respiratory distress syndrome (ARDS). VEGF inhibition may decrease hypoxia, improve endothelial permeability, and clinical trials are evaluating the role of VEGF inhibition in COVID-19.[19] Thus, anti-VEGF drugs like bevacizumab may be continued with chemotherapy subject to patients’ tolerance and treatment-emergent adverse reaction.

Low-grade serous ovarian carcinoma is usually treated with leuprolide, tamoxifen, aromatase inhibitor, trametinib, and fulvestrant.[20] These agents are relatively safe and can be continued during the COVID-19 outbreak.

Maintenance Chemotherapy

Poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib are relatively myeloid and platelet sparing as compare to rucaparib or niraparib. Olaparib with or without bevacizumab can be continued as it has been associated with a minimal risk of febrile neutropenia.[21] A higher threshold for blood product transfusions in PARP
Follow-up

Three monthly unless clinically symptomatic

Three monthly for olaparib and bevacizumab/observation for BRCA wild

Olaparib for BCRA mutant

Monthly for olaparib

Olaparib for BCRA mutant

Monthly for olaparib

Monthly for observation unless clinically symptomatic

Monthly for observation unless clinically symptomatic

Clinical scenario | Surgery | Chemotherapy | Maintenance | Follow-up |
--- | --- | --- | --- | --- |
Newly diagnosed Stage I/II | PDS | Three weekly chemotherapy | None | Three monthly unless clinically symptomatic |
Newly diagnosed Stage III/IV | Delay 4-12 weeks Interval debulking after neoadjuvant NACT preferred | Delay up to 42 days post-PDS Three weekly NACT | Bevacizumab/olaparib/ bevacizumab/observation for BRCA wild | Monthly for olaparib |
Neoadjuvant candidate | Delay 1-4 weeks | Delay adjuvant chemotherapy+bevacizumab up to 42 days post IDS | Bevacizumab+olaparib/ bevacizumab/observation for BRCA wild Olaparib for BCRA mutant | Three monthly unless clinically symptomatic |
Newly diagnosed Stage III/IV | PDS | Three weekly chemotherapy | Bevacizumab | Monthly for olaparib |
Primary debulking surgery candidate | Delay 4-12 weeks | Delay adjuvant chemotherapy+bevacizumab up to 42 days post-PDS | Bevacizumab | Three monthly unless clinically symptomatic |
Platinum sensitive relapse | Avoid/defer secondary cytoreductive surgery | Three weekly chemotherapy ± Bevacizumab | Observation | Monthly for olaparib |
Platinum-resistant relapse | Avoid/defer secondary cytoreductive surgery | Assess after 2 cycle | Bevacizumab + olaparib | Three monthly for observation unless clinically symptomatic |

PDS: Primary debulking surgery, NACT: Neoadjuvant chemotherapy

inhibitor-associated anemia may be used, and other correctable causes of anemia should be screened, such as iron, folate, and Vitamin B12 deficiency.

Immune Checkpoint Inhibitor in Ovarian Cancer

Unlike carcinoma lung, bladder, or melanoma carcinoma, epithelial ovarian cancer is less immunogenic, and in KEYNOTE 028 Ovarian cohorts, the overall response rate of an immune checkpoint inhibitor (ICI) is 11.5%. The clinico-radiologic features of an ICI-induced pneumonitis and COVID-19 pneumonia are indistinguishable. Further, in the systemic hyperinflammation stage of COVID-19 pneumonia, cytokines storm is responsible for ARDS and organ dysfunction. Patients receiving pembrolizumab (an anti-PD1 ICI) for microsatellite unstable ovarian cancer can further accelerate the immunological injury in COVID-19. In the absence of conclusive data to support or refute the use of ICI drugs in COVID-19, it will be prudent to make an informed decision to continue or stop after a detailed discussion with patients.

Follow-up and Monitoring

Those patients, who are under follow-up, can be monitored remotely by teleconsultations. The hospital visits for ultrasound, CA125 estimation can be deferred, and patients should visit the hospital only if they are symptomatic from malignancy – like rapid development of ascites and intestinal obstruction.

The crux of managing ovarian cancer amidst the outbreak is the individualized approach with informed decision-making by the patient. Trading the risk of COVID-19 with perceived benefit from chemotherapy or immunotherapy is essential. Patient education, telephonic consultation, and relocating to a non-COVID-19 affected hospital should be our approach while actively treating a patient with epithelial ovarian cancer.

In summary, modifying chemotherapy regimens, minimizing hospital visits, and individualized treatment needed for the optimal management of ovarian cancer patients during the COVID-19 pandemic.

Chandan Krushna Das¹, Shubh Mahindru², Amol Patel³, Atul Batra⁴, Bivas Biswas⁵, Prashant Mehta⁶, Raja Pramanik⁷, Sainath Bhethanabhotla⁷, Vineet Govinda Gupta⁸

¹Regional Cancer Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Surgical Oncology, Ivy Hospital, Ajitgarh, Punjab, India, ³Malignant Diseases Treatment Centre, Army Hospital Research and Referral, New Delhi, India, ⁴Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India, ⁵Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India, ⁶Department of Medical Oncology/Hematology/Bone Marrow Transplantation, Asian Institute of Medical Sciences, Faridabad, Haryana, India, ⁷Department of Medical Oncology, Krishna Institute of Medical Sciences, Secunderabad, Telangana, India, ⁸Department of Medical Oncology and Hemato-Oncology, Artemis Hospital, Gurgaon, Haryana, India

Address for correspondence:
Dr. Chandan Krushna Das,
Regional Cancer Center, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
E-mail: ckdasoncology@gmail.com

Submitted: 29-Mar-2020
Revised: 07-Apr-2020
Accepted: 09-Apr-2020
Published: 16-May-2020
References


17. Barber EL, Zsiros E, Lurain JR, Rademaker A, Schink JC, Neubauer NL. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer. J Gynecol Oncol 2013;24:258-64.


For reprints contact: WKHLRMedknow_reprints@wolterskluwer.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.